Vertex presents data demonstrating significant benefits of long-term treatment with cftr modulators at the european cystic fibrosis conference

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that 12 scientific abstracts on the company's portfolio of cystic fibrosis (cf) medicines were presented at this year's european cystic fibrosis society's (ecfs) 46th european cystic fibrosis conference held june 7-10, 2023, in vienna, austria. together, the data presented show the long-term benefits of treatment with cftr modulators as well as the importance of treating the underlying cause of cf as ear.
VRTX Ratings Summary
VRTX Quant Ranking